Trials / Completed
CompletedNCT00866736
A Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
A Phase II Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Kanto CML Study Group · Academic / Other
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and the safety of dasatinib in subject with chronic phase chronic myeloid leukemia(CML) who are either resistant to or intolerant of imatinib mesylate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dasatinib | 100mg QD |
Timeline
- Start date
- 2009-03-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2009-03-20
- Last updated
- 2015-09-15
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00866736. Inclusion in this directory is not an endorsement.